{"product_id":"antibodysystem-kda42303","title":"Vanucizumab ELISA Kit","description":"\u003cp\u003e\u003cstrong\u003eCatalog No.\u003c\/strong\u003e: KDA42303\u003c\/p\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003eCatalog No.\u003c\/th\u003e\n\u003ctd\u003eKDA42303\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct name\u003c\/th\u003e\n\u003ctd\u003eVanucizumab ELISA Kit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003ctd\u003e96 T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStability and Storage\u003c\/th\u003e\n\u003ctd\u003eThe stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eDetection method\u003c\/th\u003e\n\u003ctd\u003eColorimetric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePrecision\u003c\/th\u003e\n\u003ctd\u003eCV\u0026lt;20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSample type\u003c\/th\u003e\n\u003ctd\u003ePlasma, Serum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAssay type\u003c\/th\u003e\n\u003ctd\u003eQuantitative\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSensitivity\u003c\/th\u003e\n\u003ctd\u003e0.156 μg\/ml\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eRange\u003c\/th\u003e\n\u003ctd\u003e0.31-5 μg\/mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eRecovery\u003c\/th\u003e\n\u003ctd\u003e80-120%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eBackground\u003c\/th\u003e\n\u003ctd\u003eVanucizumab (RG7221) is an experimental humanized monoclonal antibody (mAb) designed for the treatment of cancer. Vanucizumab is a bi-specific mAb composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding vascular endothelial growth factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone. This drug was developed by Genentech\/Roche. On 12 Mar 2018, Roche completes a phase I trial in solid tumors (combination therapy, late-stage disease, metastatic disease, second-line therapy or greater) in Spain, France, and Belgium.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlternative Names\u003c\/th\u003e\n\u003ctd\u003eRG-7221, RG7221, RO5520985, CAS: 1448221-05-3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003e2-8 ℃\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eNote\u003c\/th\u003e\n\u003ctd\u003eFor Research Use Only.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"AntibodySystem","offers":[{"title":"96 T","offer_id":52602766229728,"sku":"KDA42303","price":1400.0,"currency_code":"KRW","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0601\/9330\/8896\/files\/AntibodySystem_ce86cc12-03ad-432f-ad73-88a3aab554d2.png?v=1778468280","url":"https:\/\/rndmate.com\/products\/antibodysystem-kda42303","provider":"알앤디메이트","version":"1.0","type":"link"}